Alvotech
http://www.alvotech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alvotech
And They’re Off! First Stelara Biosimilar Enters European Markets
Stada and Alvotech have heralded the start of biosimilar competition to Stelara in Europe with the launch of their partnered Uzpruvo version.
After Denosumab Deals, Alvotech Lines Up Filings
Following positive clinical trial results for its AVT03 proposed denosumab biosimilar to Prolia/Xgeva, Alvotech is planning filings in “major global markets.” Launches are expected to follow through recently-agreed partnerships.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Alvotech Partners With Advanz On European Eylea Biosimilar
Alvotech has announced its latest European biosimilars partnership, collaborating with Advanz on both 2mg and 8mg aflibercept rivals to Eylea. The deal follows several other recent alliances as well as a raise in Alvotech’s full-year revenues guidance to as much as $500m.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alvotech Iceland
- Alvotech Germany GmnH
- Alvotech Swiss AG
- Glycothera
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice